» Articles » PMID: 11758765

Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2002 Jan 5
PMID 11758765
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To study the dispersion performance of non-porous corrugated particles, with a focus on the effect of particle surface morphology on aerosolization of bovine serum albumin (BSA) powders.

Methods: The solid-state characteristics of the spray-dried BSA powders, one consisting of smooth spherical particles and another corrugated particles, were characterized by laser diffraction, X-ray powder diffraction, scanning electron microscopy, confocal microscopy, thermogravimetric analysis, surface area analyzer, and buoyancy method. The powders were dispersed using the Rotahaler and the Dinkihaler coupled to a four-stage liquid impinger operating at 30 to 120 L/min. Fine particle fraction (FPF) was expressed as the wt. % of BSA particles of size < or =5 microm collected from the liquid impinger.

Results: Apart from the morphology and morphology-related properties (specific surface area, envelope density), the corrugated particles and spherical particles of BSA had very similar solid-state characteristics (particle size distribution, water content, true density, amorphous nature). Using the Dinkihaler, the FPFs of the corrugated particles were 10-20 wt. % higher than those of the smooth particles. Similar FPF differences were found for the powders dispersed by the Rotahaler, but the relative changes were larger. In addition, the differences were inversely proportional to the air flows (17.3% at 30 L/min, 25.2% at 60 L/min, 13.8% at 90, 8.5% at 120 L/min). Depending on the inhaler, capsule and device retention and impaction loss at the impinger throat were lower for the corrugated particles.

Conclusions: Enhanced aerosol performance of powders can be obtained by surface modification of the particles. The surface asperities of the corrugated particles could lower the true area of contact between the particles, and thus reduce the powder cohesiveness. A distinct advantage of using corrugated particles is that the inhaler choice and air flow become less critical for these particles.

Citing Articles

Cannabidiol and Hydroxypropyl-β-Cyclodextrin for the Development of Deflated Spherical-Shaped Inhalable Powder.

Santos Gomes B, Bya L, Koch N, Cabral-Marques H, Evrard B, Lechanteur A AAPS J. 2025; 27(1):30.

PMID: 39825002 DOI: 10.1208/s12248-025-01015-y.


Innovative Dual Combination Cospray-Dried Rock Inhibitor/l-Carnitine Inhalable Dry Powder Aerosols.

Acosta M, Encinas-Basurto D, Abrahamson M, Eedara B, Hayes Jr D, Fineman J ACS Bio Med Chem Au. 2024; 4(6):300-318.

PMID: 39712207 PMC: 11659894. DOI: 10.1021/acsbiomedchemau.4c00063.


Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.

Salustio P, Amaral M, Costa P J Aerosol Med Pulm Drug Deliv. 2024; 37(6):307-327.

PMID: 39120712 PMC: 11669763. DOI: 10.1089/jamp.2023.0029.


Evaluating the effect of sodium alginate and sodium carboxymethylcellulose on pulmonary delivery of levofloxacin spray-dried microparticles.

Alizadeh H, Khoshhal P, Mirmoeini M, Gilani K Daru. 2024; 32(2):557-571.

PMID: 38955893 PMC: 11554959. DOI: 10.1007/s40199-024-00526-x.


Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration.

Maloney S, Stewart I, Podell B, Gary H, Mecham J, Berube B Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242512 PMC: 10220837. DOI: 10.3390/ph16050729.


References
1.
Chan H, Gonda I . Respirable form of crystals of cromoglycic acid. J Pharm Sci. 1989; 78(2):176-80. DOI: 10.1002/jps.2600780221. View

2.
Fults K, MILLER I, Hickey A . Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm Dev Technol. 1997; 2(1):67-79. DOI: 10.3109/10837459709022610. View

3.
Chew N, Bagster D, Chan H . Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm. 2000; 206(1-2):75-83. DOI: 10.1016/s0378-5173(00)00516-0. View

4.
Maa Y, Costantino H, Nguyen P, Hsu C . The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm Dev Technol. 1997; 2(3):213-23. DOI: 10.3109/10837459709031441. View

5.
Ben-Jebria A, Chen D, Eskew M, Vanbever R, Langer R, Edwards D . Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res. 1999; 16(4):555-61. DOI: 10.1023/a:1018879331061. View